The gap between trailing P/E of 14.29 and forward P/E of 18.24 suggests the market is pricing in lower near-term earnings than the trailing figures reflect, which is an inference rather than a confirmed forecast. A PEG of 0.66 appears low against a sector where Merck and Novartis trade near 1.0 to 1.5, which may indicate the market is discounting durability of growth or pricing in Inflation Reduction Act exposure. Investors should monitor whether the forward multiple compresses further as the trailing earnings base is revised.

Equity growth has outpaced borrowings, and the improvement in interest coverage points to earnings absorbing debt service more easily than two years ago, though Alexion-related debt remains the dominant balance sheet feature. Debt-to-EBITDA of 5.78 in the latest quarter remains elevated against a healthy-looking coverage ratio, which may reflect a lower interest cost environment rather than underlying deleveraging. Refinancing risk appears manageable on reported figures but warrants monitoring if rates rise again.

A current ratio near 1.0 means short-term obligations are essentially matched by current assets, leaving little margin for error if operating cash flow weakens. The quick ratio below 0.8 shows dependence on inventory and receivables conversion, which the cash conversion cycle of negative 276 days partly offsets through supplier financing. Under a severe stress scenario, the position would likely depend on continued operating inflows rather than balance sheet reserves.

The gap between ROE and ROIC is narrower than typical for a leveraged pharma business, suggesting returns on the expanded capital base remain modest in absolute terms. The improvement from roughly 2.3% ROIC in 2024Q4 indicates recovery is underway, driven largely by margin recovery rather than capital efficiency gains. Investors should watch whether ROIC can sustain movement toward double digits as Alexion intangibles continue to dilute the invested capital denominator.